Phase 3Recruiting
A Phase 3 Study of Inebilizumab in Participants With Primary Membranous Nephropathy (MOMENT)
A Phase 3 Randomized, Open-Label Multicenter Study to Evaluate Efficacy and Safety of Inebilizumab in Adult Participants With Primary Membranous Nephropathy (PMN)
- Sponsor
- Amgen (Industry)
- Enrolment
- 159 planned
- Conditions
- Glomerulonephritis, Membranous
- Interventions
- Inebilizumab; Tacrolimus
- Ages
- adults, older adults
- Registry
- NCT07851220
From the registry
The primary objective of this study to evaluate the efficacy of inebilizumab on primary membranous nephropathy (PMN) disease activity as measured by complete remission in participants with PMN.
Primary outcomes
- Percentage of Participants Achieving Complete Remission at Week 104